{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-077369","form_type":"8-K","ticker":"CPHI","cik":"0001106644","company_name":"CHINA PHARMA HOLDINGS, INC.","filed_at":"2022-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.628170+00:00","generated_at":"2026-06-21T10:04:48.086225+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"China Pharma subsidiary acquires ophthalmic oxygen therapy patent rights for $2.1M in stock","bullets":["Hainan Helpson acquires utility model patent (ZL 2022 2 0394857.6) and invention patent application for ophthalmic oxygen enriched atomization device from Chengdu Bonier.","Transfer price: RMB 15M (~$2.1M) paid via 11.1M CPHI shares at $0.1349/share within 10 days under Regulation S exemption.","Bonier provides 10-year technical services including product R&D, registration, and must secure Class II medical device registration within one year.","Service fee: 15% of net profit from product sales annually for 10 years, contingent on invention patent grant; if not granted, no service fee owed.","Stock issuance is unregistered and exempt under Regulation S; shares to a non-U.S. person in an offshore transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-077369","json":"https://secwatch.observer/filing/0001213900-22-077369.json","markdown":"https://secwatch.observer/filing/0001213900-22-077369.md","text":"https://secwatch.observer/filing/0001213900-22-077369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1106644/000121390022077369/0001213900-22-077369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1106644/000121390022077369/ea169540-8k_chinapharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T10:04:48.086225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ea33040e8d963f3fff67198af61e5d1bd3f4172","claim":"CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Contract with Chengdu Bonier Medical Technology Development Co., Ltd valued at RMB 15 million, approximately $2.1 million (effective 2022-11-28).","evidence_excerpt":"On November 28, 2022, Hainan Helpson Medical & Biotechnology Co., Ltd (“Helpson”), a wholly owned subsidiary of China Pharma Holdings, Inc. (the “Company”), entered into a Technology Transfer Contract (the “Agreement”) with Chengdu Bonier Medical Technology Development Co., Ltd (“Bonier”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1106644/000121390022077369/0001213900-22-077369-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Chengdu Bonier Medical Technology Development Co., Ltd"},{"label":"Value","value":"RMB 15 million, approximately $2.1 million"},{"label":"Effective","value":"2022-11-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}